BioMed Realty Expands Relationship With Genomic Research Pioneer J. Craig Venter

  BioMed Realty Expands Relationship With Genomic Research Pioneer J. Craig

Human Longevity and Synthetic Genomics Lease 125,300 Square Feet at 4570
Executive Drive

PR Newswire

SAN DIEGO, April 2, 2014

SAN DIEGO, April 2, 2014 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR)
today announced two expanding genomic research organizations co-founded by J.
Craig Venter will fully occupy the 4570 Executive Drive property in University
Towne Centre in San Diego, California.

BioMed Realty Trust Logo

Synthetic Genomics Inc. (SGI) will lease approximately 69,700 square feet at
BioMed Realty's 4570 Executive Drive facility to develop and commercialize
breakthrough genomic-driven solutions for major global issues. Human Longevity
Inc. (HLI), which is building and commercializing a comprehensive database of
human genotypes and phenotypes to develop treatments for aging-related
diseases and biological decline, will occupy approximately 55,600 square feet
at the 4570 Executive Drive building. In addition, HLI will continue to lease
approximately 22,200 square feet at The Research Park at Torrey Pines, located
at 10385 Road to the Cure in San Diego, California.

The J. Craig Venter Institute (JCVI) also leases approximately 122,600 square
feet at the company's 9704 Medical Center Drive property in Rockville,
Maryland. In aggregate, companies affiliated with J. Craig Venter lease more
than 270,000 square feet from BioMed Realty across the United States.

"We are very pleased to be extending our relationship with BioMed Realty and
to expand into two properties which offer modern, flexible, amenity-rich
facilities in the heart of the San Diego life science community," said J.
Craig Venter, Ph.D., Co-Founder of HLI and SGI, and Founder of JCVI. "BioMed
Realty continues to be an important partner for us and our laboratory space
needs in Maryland and California. Their commitment to deliver and operate
laboratory and office space which supports genomic-focused research, as well
as to anticipate our needs and offer creative real estate solutions, is

Commenting on the new leases, Alan Gold, BioMed Realty's Chairman and Chief
Executive Officer, remarked, "We are excited to grow our valuable, long-term
relationship with Craig Venter by forging new partnerships with Human
Longevity and Synthetic Genomics as they expand their pioneering genomic
research in San Diego. Both companies exemplify the essential value of
pursuing transformational research, which holds the promise to positively
change society in a number of important ways, including development and
commercialization of treatments and therapies which lengthen and improve the
quality of life. We look forward to supporting their groundbreaking science in
San Diego for a long time."

Concurrent with the transaction, BioMed Realty terminated its lease at 4570
Executive Drive with Bristol-Myers Squibb Company, which was previously
scheduled to expire in phases from 2015 to 2018. As a result of these new
leases, both The Research Park at Torrey Pines and 4750 Executive Drive are
now 100 percent leased.

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers
optimal real estate solutions for biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty owns or has interests in
properties comprising approximately 16.3 million rentable square feet.
Additional information is available at Follow us on
Twitter @biomedrealty.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with tax credits, grants and other subsidies to
fund development activities; risks associated with downturns in foreign,
domestic and local economies, changes in interest rates and foreign currency
exchange rates, and volatility in the securities markets; ownership of
properties outside of the United States that subject the company to different
and potentially greater risks than those associated with the company's
domestic operations; risks associated with the company's investments in loans,
including borrower defaults and potential principal losses; potential
liability for uninsured losses and environmental contamination; risks
associated with the company's potential failure to qualify as a REIT under the
Internal Revenue Code of 1986, as amended, and possible adverse changes in tax
and environmental laws; and risks associated with the company's dependence on
key personnel whose continued service is not guaranteed. For a further list
and description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The
company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Logo -

SOURCE BioMed Realty

Contact: Jim Cullinan, (858) 485-9840,
Press spacebar to pause and continue. Press esc to stop.